REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Cancer-Associated Thrombosis (CAT)

In brief

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Key facts

Study ID
NCT07410117
Run by
Regeneron Pharmaceuticals
People needed
1120
Starts
2026-03-09
Expected to finish
2030-05-06
Last updated by the study team
2026-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.